Wereport a case of tertiary hyperparathyroidism in an X-linked familial hypophosphatemic rickets (XLH) patient under regular calcitriol and self-adjusted large doses of oral phosphate salt (2.4-3.6 g/day in 4-5 divided doses) according to his serum phosphate level. Tertiary hyperparathyroidism is an unusual complication of XLHpatients during treatment. As there is growing evidence that a high phosphate diet may induce hyperplasia of the parathyroid glands, it is important to avoid the stimulation of the parathy roid glands by high doses of phosphate administration in XLHpatients. Serum calcium, phosphate, alkaline phosphatase, and also parathyroid hormoneshould be measured regularly in order to facilitate an early diagnosis of secondary hyperparathyroidism during the treatment of XLH patients, since this stage is reversible with calcitriol and reduced doses of phosphate salt.
Introduction
Secondary or tertiary hyperparathyroidism is often recognized in end-stage renal disease. However, chronic low serum ionized calcium levels seen in osteomalacia or rickets may stimulate parathyroid gland secretion and ultimately result in secondary or tertiary hyperparathyroidism. The exact prevalence and pathophysiology for the development of secondary or tertiary hyperparathyroidism in these patients is still unclear.
Thus we report an X-linked familial hypophosphatemic rickets (XLH) patient with tertiary hyperparathyroidism, and note the early development of this complication under the combined therapy of vitamin D (calcitriol : 1 ,25 -dihydroxycholecalciferol) and large doses of oral phosphate salt in XLHpatients.
For editorial comment, see p 440.
Case Report
A 16-year-old male was brought to our clinic for evaluation of right shoulder pain. He was an XLHpatient, which was diagnosed at 1.5 years old with the complaints of short stature, poor weight gain and characteristic roentgenographic findings as widening and flaying of metaphysis over both knee and ankle joints (Fig. 1 ). His cousin is also an XLHpatient. After supplementation with vitamin D (calcitriol 0.5 microgram/day) and oral phosphate salt, his condition improved. His serum alkaline phosphatase level was normalized step by step, although there were frequent episodes of hypocalcemic twitching observed (see Fig. 2 , first 4 years). Thereafter, only serum calcium, phosphate and alkaline phosphatase were checked by his physician. During his teenage years, although he did not have regular medical consultations, he use regular calcitriol and self-adjusted large doses of oral phosphate salt (2.4-3.6 g/ day in 4-5 divided doses) according to his serum phosphate level. Since the age of 10-ll years, he occasionally felt general body aches with abnormal results of his blood biochemistry (low serum phosphate, mild hypercalcemia and elevated serum alkaline phosphatase levels). He did not pay much attention to this and just thought that the low serum phosphate and the elevated serum alkaline phosphatase levels were related to the disease process of XLH.Thus he had self-adjusted his medication to diminished calcitriol and elevated oral phosphate salt doses in the subsequent years without further medical consultation. On examination, he had a short stature (146 cm), frontal bossing of the cranium, bulging of the costochondral junctions (rachitic rosary) and bowing of the lower limbs. A mildly tender right shoulder was found without evidence of fracture, but X-ray of fingers showed mild subperiosteal resorption and osteopenic change ( thyroid hormone, analyzed by IMMULITEchemiluminescent immunometric assay, DPC, Los Angeles, USA) was 1,650 pg/ ml (normal as 12-72 pg/ml), with simultaneous serum levels of calcium at ll.1 mg/dl (normal as 8.9-10.4 mg/dl) and phosphate at 2.5 mg/dl (normal as 3.0-4.6 mg/dl). The serum level of alkaline phosphatase was also very high at 2,795 IU//. Other available parameters, such as serum creatinine, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, were all within normal limits during continuous oral phosphate salt and calcitriol usage (Table 1) . Thus tertiary hyperparathyroidism associated with XLHwas impressed after exclusion of renal insufficiency. The retrospective summaryof serum calcium, phosphate and alkaline phosphatase since birth and concomitant medication regimen were plotted (Fig. 2) . Multiglandular parathyroid hyperplasia was found on sonography, but to date, his family has refused surgery. (6) . In tertiary hyperparathyroidism of XLHpatients, the serum calcium level is usually normal or mildly elevated and the phosphate is low because of phosphate diuresis by PTHaction, as seen in the present case. In autonomous tertiary hyperparathyroidism, it is theoretically necessary to perform parathyroidectomy. The optimal treatment for XLHpatients has not yet been established. However, combined therapy of oral phosphate salt and calcitriol is the best therapeutic approach at present. Vitamin D usage heals the bone lesions and phosphate salt supplement contributes to better mineralization and improvedgrowth velocity. But secondary or tertiary hyperparathyroidism is a potential complication during the treatment of XLHpatients. Figure 2 . Summaryof laboratory results and medication dose. Mildly elevated serum phosphate level with relative hypocalcemia was present before age 10 under combined usage of vitamin Dand phosphate salt. Since the age of 10, he has self-adjusted his phosphate dose to 2.4-3.6 g/day (as compared to previous doses of 1.6-2.4 g/day) with persistent mild hypercalcemia and a low phosphate level, that was due to the development of tertiary hyperparathyroidism. Serum PTHvalue was not monitored from age 4 to 16 (PTH value was 55.39 ng/ml at age 4).
ages ranging from 16 to 53 years old (7) . The exact frequency of tertiary hyperparathyroidism in XLHpatients is still unclear.
However, there seems to be a higher incidence of the early Figure 3 . Subperiosteal resorption and osteopenic change over finger phalanges is shown in A, and illustrated in B. 
